The same outside adviser, who was unidentified in Tuesday's release, advised that a package of assistance programs to patients would: «force reporters to focus on the byzantine
nature of drug pricing and health care and ensure the patient message gets out... specifically tie profits from Daraprim to the research and development of a new and more effective treatment for Daraprim patients.
It is either testament to a great writing job by Werth, or the very real and harrowing
nature of Vertex's journey that when Wysenki announces the
price for Incivek, $ 49,200 for a twelve - week course
of the
drug, that the reader thinks for a moment, is that all?